IL175611A0 - Combinations for the treatment of proliferative diseases - Google Patents

Combinations for the treatment of proliferative diseases

Info

Publication number
IL175611A0
IL175611A0 IL175611A IL17561106A IL175611A0 IL 175611 A0 IL175611 A0 IL 175611A0 IL 175611 A IL175611 A IL 175611A IL 17561106 A IL17561106 A IL 17561106A IL 175611 A0 IL175611 A0 IL 175611A0
Authority
IL
Israel
Prior art keywords
combinations
treatment
proliferative diseases
proliferative
diseases
Prior art date
Application number
IL175611A
Other languages
English (en)
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/855,130 external-priority patent/US20050100508A1/en
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of IL175611A0 publication Critical patent/IL175611A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL175611A 2003-11-12 2006-05-11 Combinations for the treatment of proliferative diseases IL175611A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51955103P 2003-11-12 2003-11-12
US10/855,130 US20050100508A1 (en) 2003-11-12 2004-05-27 Methods for identifying drug combinations for the treatment of proliferative diseases
PCT/US2004/037527 WO2005046607A2 (en) 2003-11-12 2004-11-09 Combinations for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
IL175611A0 true IL175611A0 (en) 2008-04-13

Family

ID=34556562

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175611A IL175611A0 (en) 2003-11-12 2006-05-11 Combinations for the treatment of proliferative diseases

Country Status (13)

Country Link
EP (1) EP1689352A2 (ja)
JP (1) JP2007524657A (ja)
KR (1) KR20060118514A (ja)
AR (1) AR046841A1 (ja)
AU (1) AU2004289311A1 (ja)
BR (1) BRPI0416390A (ja)
CA (1) CA2545423A1 (ja)
IL (1) IL175611A0 (ja)
IS (1) IS8496A (ja)
NO (1) NO20062358L (ja)
RU (1) RU2006120491A (ja)
TW (1) TW200526777A (ja)
WO (1) WO2005046607A2 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070865A1 (es) * 2008-03-18 2010-05-12 Genentech Inc Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
WO2005046607A3 (en) 2012-12-20
IS8496A (is) 2006-06-02
JP2007524657A (ja) 2007-08-30
RU2006120491A (ru) 2007-12-20
KR20060118514A (ko) 2006-11-23
EP1689352A2 (en) 2006-08-16
TW200526777A (en) 2005-08-16
NO20062358L (no) 2006-07-12
CA2545423A1 (en) 2005-05-26
AU2004289311A1 (en) 2005-05-26
AR046841A1 (es) 2005-12-28
WO2005046607A2 (en) 2005-05-26
BRPI0416390A (pt) 2007-02-21

Similar Documents

Publication Publication Date Title
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
EP1613308A4 (en) CANCER TREATMENT METHODS
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL176028A0 (en) Compounds for treatment of cell proliferative diseases
ZA200508427B (en) Methods for treating interleuking-6 related diseases
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
GB0316912D0 (en) Therapeutic treatment
EP1789034A4 (en) COMPOUNDS HAVING A DIPHENYL STRUCTURE FOR THE TREATMENT OF IMMUNE DISEASES
GB0320806D0 (en) Therapeutic treatment
GB0329874D0 (en) Compounds useful for the treatment of diseases
SI1685125T1 (sl) Derivati pirola, primerni za zdravljenje proliferativnih bolezni
EP1611120A4 (en) NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
GB0307863D0 (en) Therapeutic treatment
IL175611A0 (en) Combinations for the treatment of proliferative diseases
GB0313772D0 (en) Therapeutic treatment
ZA200606780B (en) Compounds for the treatment of diseases
GB0216097D0 (en) Treatment of proliferative disorders
SI1535612T1 (sl) Zdravljenje hiperurikemije
GB0420867D0 (en) Compounds for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases